家族性高胆固醇血症 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "家族性高胆固醇血症" in Chinese language version.

refsWebsite

Global rank Chinese rank

11nih.gov

4^th place

5^th place

11doi.org

2^nd place

23^rd place

3archive.org

6^th place

4^th place

1archive.today

14^th place

18^th place

1jaoa.org

low place

1wikipedia.org

low place

1nice.org.uk

3,258^th place

2,433^rd place

1oxfordjournals.org

1,389^th place

860^th place

1web.archive.org

1^st place

archive.org

Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 2003, 111 (12): 1795–803. PMC 161432 . PMID 12813012. doi:10.1172/JCI18925.
Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 2004, 256 (6): 482–90. PMID 15554949. doi:10.1111/j.1365-2796.2004.01405.x.
Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J. Clin. Invest. 1986, 78 (5): 1410–4. PMC 423848 . PMID 3771801. doi:10.1172/JCI112729.

archive.today

Repas TB, Tanner JR. Preventing early cardiovascular death in patients with familial hypercholesterolemia. J Am Osteopath Assoc. February 2014, 114 (2): 99–108 [2015-09-19]. PMID 24481802. doi:10.7556/jaoa.2014.023. （原始内容存档于2014-03-11）.

doi.org

Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 2003, 111 (12): 1795–803. PMC 161432 . PMID 12813012. doi:10.1172/JCI18925.
Tsouli SG, Kiortsis DN, Argyropoulou MI, Mikhailidis DP, Elisaf MS. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur. J. Clin. Invest. 2005, 35 (4): 236–44. PMID 15816992. doi:10.1111/j.1365-2362.2005.01484.x.
Durrington P. Dyslipidaemia. Lancet. 2003, 362 (9385): 717–31. PMID 12957096. doi:10.1016/S0140-6736(03)14234-1.
Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 2004, 256 (6): 482–90. PMID 15554949. doi:10.1111/j.1365-2796.2004.01405.x.
Repas TB, Tanner JR. Preventing early cardiovascular death in patients with familial hypercholesterolemia. J Am Osteopath Assoc. February 2014, 114 (2): 99–108 [2015-09-19]. PMID 24481802. doi:10.7556/jaoa.2014.023. （原始内容存档于2014-03-11）.
Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDLR gene in familial hypercholesterolemia. Hum. Mutat. 1992, 1 (6): 445–66. PMID 1301956. doi:10.1002/humu.1380010602.
Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J. Clin. Invest. 1986, 78 (5): 1410–4. PMC 423848 . PMID 3771801. doi:10.1172/JCI112729.
Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc. Natl. Acad. Sci. U.S.A. 1974, 71 (3): 788–92. PMC 388099 . PMID 4362634. doi:10.1073/pnas.71.3.788.
Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. April 2008, 358 (14): 1431–43. PMID 18376000. doi:10.1056/NEJMoa0800742.
Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis. 1999, 142 (1): 105–12. PMID 9920511. doi:10.1016/S0021-9150(98)00200-7.
Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. November 2008, 29 (21): 2625–33 [2015-09-18]. PMC 2577142 . PMID 18840879. doi:10.1093/eurheartj/ehn422. （原始内容存档于2016-12-20）.

jaoa.org

Repas TB, Tanner JR. Preventing early cardiovascular death in patients with familial hypercholesterolemia. J Am Osteopath Assoc. February 2014, 114 (2): 99–108 [2015-09-19]. PMID 24481802. doi:10.7556/jaoa.2014.023. （原始内容存档于2014-03-11）.

nice.org.uk

guidance.nice.org.uk

National Institute for Health and Clinical Excellence（英语：National Institute for Health and Clinical Excellence）. Clinical guideline 71: Familial hypercholesterolaemia. London, 2008.

nih.gov

ncbi.nlm.nih.gov

Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 2003, 111 (12): 1795–803. PMC 161432 . PMID 12813012. doi:10.1172/JCI18925.
Tsouli SG, Kiortsis DN, Argyropoulou MI, Mikhailidis DP, Elisaf MS. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur. J. Clin. Invest. 2005, 35 (4): 236–44. PMID 15816992. doi:10.1111/j.1365-2362.2005.01484.x.
Durrington P. Dyslipidaemia. Lancet. 2003, 362 (9385): 717–31. PMID 12957096. doi:10.1016/S0140-6736(03)14234-1.
Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 2004, 256 (6): 482–90. PMID 15554949. doi:10.1111/j.1365-2796.2004.01405.x.
Repas TB, Tanner JR. Preventing early cardiovascular death in patients with familial hypercholesterolemia. J Am Osteopath Assoc. February 2014, 114 (2): 99–108 [2015-09-19]. PMID 24481802. doi:10.7556/jaoa.2014.023. （原始内容存档于2014-03-11）.
Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDLR gene in familial hypercholesterolemia. Hum. Mutat. 1992, 1 (6): 445–66. PMID 1301956. doi:10.1002/humu.1380010602.
Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J. Clin. Invest. 1986, 78 (5): 1410–4. PMC 423848 . PMID 3771801. doi:10.1172/JCI112729.
Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc. Natl. Acad. Sci. U.S.A. 1974, 71 (3): 788–92. PMC 388099 . PMID 4362634. doi:10.1073/pnas.71.3.788.
Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. April 2008, 358 (14): 1431–43. PMID 18376000. doi:10.1056/NEJMoa0800742.
Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis. 1999, 142 (1): 105–12. PMID 9920511. doi:10.1016/S0021-9150(98)00200-7.
Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. November 2008, 29 (21): 2625–33 [2015-09-18]. PMC 2577142 . PMID 18840879. doi:10.1093/eurheartj/ehn422. （原始内容存档于2016-12-20）.

oxfordjournals.org

eurheartj.oxfordjournals.org

Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. November 2008, 29 (21): 2625–33 [2015-09-18]. PMC 2577142 . PMID 18840879. doi:10.1093/eurheartj/ehn422. （原始内容存档于2016-12-20）.

web.archive.org

Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. November 2008, 29 (21): 2625–33 [2015-09-18]. PMC 2577142 . PMID 18840879. doi:10.1093/eurheartj/ehn422. （原始内容存档于2016-12-20）.

wikipedia.org

en.wikipedia.org

National Institute for Health and Clinical Excellence（英语：National Institute for Health and Clinical Excellence）. Clinical guideline 71: Familial hypercholesterolaemia. London, 2008.